GeneDx Holdings Corp. (WGS) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

WGS — Fair Value Analysis

GeneDx Holdings Corp.

Current: $77.39Overvalued

Fair Value Range

Bear Case (25th pct.)

$-10.98

-114.2% vs price

Base Case (Median)

$-6.50

-108.4% vs price

Bull Case (75th pct.)

$-2.02

-102.6% vs price

$-10.98$-6.50$-2.02

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$-15.47	-120.0%	High (40%)
EV/EBITDA	$2.46	-96.8%	Medium (20%)

Interpretation

Based on 2 out of 8 methods, WGS appears overvalued at the current price of $77.39. The base case fair value of $-6.50 implies 108.4% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.